Stefin A Nanoconjugates for Selective Auristatin Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapy methods face challenges due to tumor resistance and side effects, necessitating the development of more specific therapeutic approaches that can target concrete tumor cells while minimizing off-target effects.
Innovation Solution
A fusion protein comprising a polycationic peptide, Stefin A or its variant, and a positively charged amino acid-rich region conjugated to an auristatin molecule, which functions as an effective target-selective delivery system for therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy methods are used, then tumor cells can be treated, but tumor resistance develops and side effects occur
Solution Approach 1:
The invention segments the therapeutic approach by separating the cytotoxic agent (auristatin) from the delivery system (fusion protein nanoparticle). This allows the drug to be delivered selectively to tumor cells through the polycationic peptide component, while the cytotoxic payload remains contained until release at the target site, thereby reducing off-target side effects and overcoming resistance mechanisms.
Solution Approach 2:
The fusion protein acts as an intermediary carrier between the bloodstream and tumor cells. The polycationic peptide component mediates cellular uptake and targeting, while the Stefin A core provides structural stability and nanoparticle formation. This intermediary system enables selective delivery of auristatin to tumor cells, enhancing therapeutic effectiveness while minimizing systemic toxicity.
2Reliability
If antibody-drug conjugates are used to achieve selective delivery, then therapeutic impact is enhanced, but structural complexity and synthesis cost increase
Solution Approach 1:
The invention extracts and removes the complex antibody structure from the conjugate system, replacing it with a simplified fusion protein based on Stefin A. This extraction maintains the essential function of selective targeting through the polycationic peptide while eliminating the structural complexity and high synthesis costs associated with full antibody molecules.
Solution Approach 2:
The fusion protein nanoparticle serves as a disposable, single-use delivery vehicle that is structurally simpler and less expensive to produce than antibody-based conjugates. The nanoparticle delivers its payload and is then degraded, eliminating the need for complex, reusable antibody structures while achieving comparable selective delivery functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion protein enhances the selective delivery of therapeutic agents to cancer cells, increasing mitotic catastrophe and demonstrating higher antitumor activity compared to unconjugated proteins, thereby addressing tumor resistance and reducing side effects.
Implementation Method 1
The resulting drug loaded conjugates sizing between 8 and 100 nm escape from renal filtration in absence of aggregation in lung or other highly vascularized organs
Implementation Method 2
When administered systemically, the resulting drug loaded conjugates sizing between 8 and 100 nm escape from renal filtration
Data Source
AI summary
The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.